JameelMuzaffarMD

Endocrine Cancer, Head & Neck Cancer

Assistant Member and Clinical Assistant Professor, Moffitt Cancer Center

Dr. Muzaffar is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

PubMed

Nemvaleukin alfa, a modified interleukin-2 cytokine, as monotherapy and with pembrolizumab in patients with advanced solid tumors (ARTISTRY-1).
Ulka N Vaishampayan, Jameel Muzaffar, Ira Winer, Seth D Rosen, Christoper J Hoimes
Journal for Immunotherapy of Cancer. 2024-11-20
1 citations
Cabozantinib plus ipilimumab/nivolumab in patients with previously treated advanced differentiated thyroid cancer.
Bhavana Konda, Eric J Sherman, Erminia Massarelli, Jorge Nieva, Jameel Muzaffar
The Journal of Clinical Endocrinology and Metabolism. 2024-08-12
Author Correction: Pembrolizumab and cabozantinib in recurrent metastatic head and neck squamous cell carcinoma: a phase 2 trial.
Nabil F Saba, Conor E Steuer, Asari Ekpenyong, Ashley McCook-Veal, Kelly Magliocca
Nature Medicine. 2024-08-01

Lectures

A phase II study of capecitabine (Cape) or 5-fluorouracil (5-FU) with pegylated interferon alpha-2b (Peg-IFNA-2b) in unresectable/metastatic cutaneous squamous cell ca...
2019 ASCO Annual Meeting - 6/1/2019

Next-Generation Immunotherapy Drug Shows Continued Promise in Several Advanced-Stage CancersMay 26th, 2022